[
    [
        {
            "time": "2021-10-20",
            "original_text": "恒瑞医药前三季度净利负增长18年首降,近三月研发支出15.6亿,管理费用砍掉5成 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "净利负增长",
                    "研发支出",
                    "管理费用",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药前三季度净利负增长18年首降,近三月研发支出15.6亿,管理费用砍掉5成 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "恒瑞医药：创新＋国际化齐头并进，加快实现转型升级",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "创新",
                    "国际化",
                    "转型",
                    "升级"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：创新＋国际化齐头并进，加快实现转型升级",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "恒瑞医药三季度营收净利双降 研发一哥迎上市以来最强挑战 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "营收净利双降",
                    "研发",
                    "挑战",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药三季度营收净利双降 研发一哥迎上市以来最强挑战 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "恒瑞医药单季度营收16年后再现同比下降，北向资金连续三季度减持 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "单季度营收",
                    "同比下降",
                    "北向资金",
                    "减持",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药单季度营收16年后再现同比下降，北向资金连续三季度减持 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "西南证券维持恒瑞医药买入评级：集采短期持续影响业绩，全面拥抱创新与国际化",
            "features": {
                "keywords": [
                    "西南证券",
                    "恒瑞医药",
                    "买入评级",
                    "集采",
                    "业绩影响",
                    "创新",
                    "国际化"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券维持恒瑞医药买入评级：集采短期持续影响业绩，全面拥抱创新与国际化",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "华鑫证券维持恒瑞医药推荐评级：收入增速放缓，全面创新升级 盈利能力下降",
            "features": {
                "keywords": [
                    "华鑫证券",
                    "恒瑞医药",
                    "推荐评级",
                    "收入增速放缓",
                    "创新升级",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华鑫证券维持恒瑞医药推荐评级：收入增速放缓，全面创新升级 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "恒瑞医药三季度营收净利双降 “医药一哥”市值腰斩 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "三季度",
                    "营收净利双降",
                    "医药一哥",
                    "市值腰斩",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药三季度营收净利双降 “医药一哥”市值腰斩 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "前三季盈利微降，顶着集采压力的恒瑞医药继续大手笔搞研发 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "前三季",
                    "盈利微降",
                    "集采压力",
                    "研发",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "前三季盈利微降，顶着集采压力的恒瑞医药继续大手笔搞研发 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "Q3业绩落地 恒瑞医药由跌转升",
            "features": {
                "keywords": [
                    "Q3业绩",
                    "恒瑞医药",
                    "由跌转升"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Q3业绩落地 恒瑞医药由跌转升",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-20",
            "original_text": "安信证券：予恒瑞医药“增持-A”评级 目标价73.37元",
            "features": {
                "keywords": [
                    "安信证券",
                    "恒瑞医药",
                    "增持-A",
                    "目标价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "安信证券：予恒瑞医药“增持-A”评级 目标价73.37元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]